Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials
- PMID: 30864461
- DOI: 10.1177/0004867419835028
Adjunctive use of anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials
Abstract
Objective: Recent evidence suggests that adjuvant anti-inflammatory agents could improve the symptoms of patients with schizophrenia. However, the effects of the adjuvant anti-inflammatory agents on cognitive function, general functioning and side effects have not yet been systematically investigated. The present meta-analysis aimed to explore the effects of anti-inflammatory agents in patients with schizophrenia comprehensively.
Method: We performed a literature search in online databases, including PubMed, EMBASE and the Cochrane Database of Systematic Reviews. Randomized, placebo-controlled double-blind studies that investigated clinical outcomes including psychopathology, neurocognition, general functioning and extrapyramidal side effects were included. The examined anti-inflammatory agents included aspirin, celecoxib, omega-3 fatty acids, estrogen, selective estrogen receptor modulator, pregnenolone, N-acetylcysteine, minocycline, davunetide and erythropoietin.
Results: Sixty-two double-blind randomized clinical trials studying 2914 patients with schizophrenia met the inclusion criteria for quantitative analysis. Significant overall effects were found for anti-inflammatory agents for reducing total, positive and negative symptom scores in the Positive and Negative Syndrome Scale. Cognitive improvements were significant with minocycline and pregnenolone augmentation therapy. General functioning was significantly enhanced by overall anti-inflammatory agents. There were no significant differences in side effects compared with placebo. Baseline total Positive and Negative Syndrome Scale score and illness duration were identified as moderating factors in the effects of anti-inflammatory augmentation on psychiatric symptom improvements.
Conclusion: The comparative evaluation of efficacy and safety supported the use of anti-inflammatory adjuvant therapy over the use of antipsychotics alone. However, future studies could focus on patients with homogeneous clinical profile to figure out more detailed effects of anti-inflammatory therapy.
Keywords: Schizophrenia; anti-inflammatory agents; meta-analysis; randomized controlled trials.
Similar articles
-
Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.Psychiatry Clin Neurosci. 2014 Jun;68(6):432-40. doi: 10.1111/pcn.12150. Epub 2014 Feb 18. Psychiatry Clin Neurosci. 2014. PMID: 24548129 Clinical Trial.
-
Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis.J Clin Psychiatry. 2012 Apr;73(4):414-9. doi: 10.4088/JCP.10r06823. Epub 2011 Dec 13. J Clin Psychiatry. 2012. PMID: 22225599
-
An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis.Psychol Med. 2019 Oct;49(14):2307-2319. doi: 10.1017/S0033291719001995. Epub 2019 Aug 23. Psychol Med. 2019. PMID: 31439071 Free PMC article. Review.
-
Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.Schizophr Res. 2007 Feb;90(1-3):179-85. doi: 10.1016/j.schres.2006.11.016. Epub 2007 Jan 8. Schizophr Res. 2007. PMID: 17208413 Clinical Trial.
-
Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis.Int J Neuropsychopharmacol. 2018 Aug 1;21(8):748-757. doi: 10.1093/ijnp/pyy045. Int J Neuropsychopharmacol. 2018. PMID: 29762677 Free PMC article.
Cited by
-
European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.Eur Psychiatry. 2022 Sep 5;65(1):e57. doi: 10.1192/j.eurpsy.2022.2315. Eur Psychiatry. 2022. PMID: 36059103 Free PMC article. Review.
-
Peripheral complement proteins in schizophrenia: A systematic review and meta-analysis of serological studies.Schizophr Res. 2020 Aug;222:58-72. doi: 10.1016/j.schres.2020.05.036. Epub 2020 May 24. Schizophr Res. 2020. PMID: 32456884 Free PMC article.
-
Circulating microRNA Profiles Identify a Patient Subgroup with High Inflammation and Severe Symptoms in Schizophrenia Experiencing Acute Psychosis.Int J Mol Sci. 2024 Apr 12;25(8):4291. doi: 10.3390/ijms25084291. Int J Mol Sci. 2024. PMID: 38673876 Free PMC article.
-
Plasma microRNAs Associate Positive, Negative, and Cognitive Symptoms with Inflammation in Schizophrenia.Int J Mol Sci. 2024 Dec 17;25(24):13522. doi: 10.3390/ijms252413522. Int J Mol Sci. 2024. PMID: 39769285 Free PMC article.
-
Immune-neuroendocrine crosstalk in mood and psychotic disorders: A meta-analysis and systematic review.Brain Behav Immun Health. 2025 Feb 11;44:100965. doi: 10.1016/j.bbih.2025.100965. eCollection 2025 Mar. Brain Behav Immun Health. 2025. PMID: 40040865 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous